ABBOTT PARK, Ill., June 26, 2020
/PRNewswire/ -- Abbott (NYSE: ABT) today announced new data from
the company's LightLab Initiative that showed optical coherence
tomography (OCT) imaging significantly changes how physicians
decide to treat a vessel compared to traditional angiography by
providing physicians improved visualization within a patient's
blood vessels. Data from the study revealed physicians altered
their treatment strategy in 88% of coronary artery blockages based
on new information provided by OCT.
Using laser technology, OCT captures high-resolution images
inside a patient's arteries, displaying the type and severity of
disease in the vessel, as well as enabling more accurate
measurements to determine how the patient should be treated.
"After planning a procedure with angiography alone, we exposed
physicians to all the information provided by OCT on the same
blockage and were able to demonstrate the significant impact that
the information had on our decisions," said Hiram Bezerra, M.D., professor of medicine at
the University of South Tampa and
the director of Cardiac Interventional Services at Tampa General
Hospital in Florida. "OCT takes
the guesswork out of angiography, offering doctors real-time
high-quality granularity and precision when performing PCIs, and
helping doctors make real-time decisions in the cath lab."
This is the first data release from Abbott's LightLab
Initiative, which was presented as part of a virtual three-day PCR
e-Course held by the European Association of Percutaneous
Cardiovascular Interventions (EAPCI), June
25-27. The new data provides strong evidence of the value of
using OCT for decision-making within the PCI procedure. Initial
data found:
- OCT changes angiographic-based decisions in 88% of
lesions.
- After deploying a stent, physicians made changes in treating
31% of lesions based on OCT information to treat damage to the
artery previously invisible with angiography alone.
- Physicians improved their assessment of potential blockages as
a result of using OCT, which better helped inform which size of
stent to use and optimal stent deployment compared with angiography
alone.
"The LightLab Initiative has given us great insights into the
challenges facing interventional cardiologists in the cath lab and
the impact OCT can have on the decisions physicians make in
treating their patients," said Nick
West, M.D., divisional vice president, Medical Affairs, and
chief medical officer of Abbott's vascular business. "The data has
also highlighted how effective OCT can be at treating patients with
complex cardiovascular disease with greater precision."
About the LightLab Initiative
The LightLab Initiative was designed to examine the role and
impact of OCT on physician decision-making, procedural efficiency
and procedural safety over angiography during procedures for
patients with vascular disease. Abbott field clinical
engineers collaborated with interventional cardiologists in 12
medical centers across the United
States and collected PCI procedural data over a 12-month
period.
Of the 2,203 procedures and 1,016 interventions that were
assessed in the first phase of the LightLab Initiative, doctors
used OCT before and after stenting in 652 lesions.
The level of detail and the volume of data collected in this
real-world patient cohort demonstrates a clear and important impact
of OCT on lesion assessment, procedural planning and stent
optimization, with further analyses from subsequent phases of the
program planned in coming months. The subsequent phases of the
LightLab Initiative will focus on optimizing the prescribed
treatment steps when using OCT to achieve greater efficiency
(shorter timing) and safety (lower contrast and radiation exposure)
gains, thereby identifying and removing barriers to OCT
adoption.
About Optical Coherence Tomography
OCT is an intracoronary imaging platform that uses light-based
technology to help characterize and assess coronary arteries from
inside the vessel with high precision, allowing for assessment of
the degree and characteristics of coronary artery disease, accurate
dimensional measurement of the artery and assessment of the quality
of stent deployment2.
About Abbott
Abbott is a global healthcare leader that helps people live more
fully at all stages of life. Our portfolio of life-changing
technologies spans the spectrum of healthcare, with leading
businesses and products in diagnostics, medical devices,
nutritionals and branded generic medicines. Our 103,000 colleagues
serve people in more than 160 countries.
Connect with us at www.abbott.com, on LinkedIn at
www.linkedin.com/company/abbott-/, on Facebook at
www.facebook.com/Abbott and on Twitter @AbbottNews and
@AbbottGlobal
1 Jones, Daniel A. et al "Angiography
Alone Versus Angiography Plus Optical Coherence Tomography
to Guide
Percutaneous Coronary Intervention." JACC:
Cardiovascular
Interventions 11.14 (2018): 1313-1321. Web.
23 Aug. 2018.
2
https://www.cathlabdigest.com/content/next-innovation-pci-not-stent-value-optical-coherence-tomography-oct
View original
content:http://www.prnewswire.com/news-releases/new-research-finds-abbotts-optical-coherence-tomography-imaging-changed-treatment-decisions-in-88-of-artery-blockages-301084234.html
SOURCE Abbott